𝔖 Bobbio Scriptorium
✦   LIBER   ✦

386 POSTER Pharmacokinetic (PK) and pharmacodynamic (PD) phase I study of an oral c-Met inhibitor ARQ197 reaches maximum tolerated dose (MTD) in a twice daily (bid) dosing schedule

✍ Scribed by T.A. Yap; J. Barriuso; S. Frentzas; R. Riisnaes; J. Clark; J. Dukes; A. Futreal; R.E. Savage; F. Chai; J.S. de Bono


Book ID
119599542
Publisher
Elsevier Science
Year
2008
Tongue
English
Weight
62 KB
Volume
6
Category
Article
ISSN
1359-6349

No coin nor oath required. For personal study only.